A Multicenter, Open Label Phase II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AK120 in Adolescents With Moderate-to-severe AD
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs Manfidokimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Akeso Biopharma
- 08 Jan 2025 New trial record